Safety and Efficacy of Urtica Dioica Cataplasm in the Management of Osgood-Schlatter Disease in Y… (NCT07096037) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Safety and Efficacy of Urtica Dioica Cataplasm in the Management of Osgood-Schlatter Disease in Young Athletes
90 participantsStarted 2025-09-01
Plain-language summary
The primary objective of this clinical trial is to evaluate the efficacy and safety of a topical Urtica dioica cataplasm in managing knee pain and functional limitations in athletic children diagnosed with Osgood-Schlatter Disease. Efficacy will be assessed through changes in knee pain using the Visual Analog Scale (VAS) and functional outcomes using the Knee Injury and Osteoarthritis Outcome Score (KOOS). Three groups will be tested:
* UDC Group: topical application of Urtica dioica cataplasm
* Standard Care Group: oral vitamin D supplementation and physical rest
* Placebo Group: topical application of a placebo cataplasm using Beta vulgaris subsp. cicla
Who can participate
Age range
7 Years – 15 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Healthy male children between 7 and 15 years of age
* Active in regular sports practice (e.g., football)
* Clinically confirmed diagnosis of OSD
Exclusion Criteria:
* Known allergy to Urtica dioica
* Presence of dermatological conditions or lesions on the knees
* Recent use of anti-inflammatory medications
* History of immune or chronic inflammatory diseases
* Diagnosis of any other bone disorder
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this trial is testing a stinging nettle (Urtica dioica) cataplasm — essentially a medicated compress applied to the skin — can you help me understand how this approach might compare to the rest and physical therapy options you'd normally recommend for Osgood-Schlatter Disease?
2This trial is listed as 'not yet recruiting,' which means it hasn't started enrolling patients — is this something worth revisiting later, or would waiting potentially delay my child's treatment at a critical time in their growth?
3The trial is in Phase NA and is measuring pain intensity as its main outcome — what does that tell us about how much is already known regarding the safety of applying this plant-based compress to a young athlete's knee, and are there any skin sensitivity risks I should know about?
4Since Osgood-Schlatter Disease often improves on its own with rest and activity modification, do you think the standard approach would be a better first step for my child before considering an experimental herbal treatment like this one?
5If my child were to participate in this trial once it opens, how would it affect their sports schedule, and would they need to stop other treatments they're already using for the pain?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Pain intensity
Timeframe: At each clinical visit during the intervention period (three times a week during 6 weeks).